Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 9, 2003

View Archived Issues

Guangdong Medicine Group signs agreement for Alferon N and Ampligen

Ciprofloxacin GR as effective as Cipro for UTIs

Multiferon gives positive in vitro results against SARS

Good safety and pharmacokinetic profile for oral insulin in type 1 diabetes

High compliance rate, no effects on lung function reported for inhaled insulin in type 2 diabetes

Analgesic efficacy described for LAS-34475 in a model of acute dental pain

Increased insulin sensitivity and glycemic control associated with chromium in type 2 diabetes

GSK scientists identify novel surfactants for inhalable aerosols

Novel GnRH modulators prepared and tested by Pfizer researchers

Biphenyl-based antiandrogenic agents covered by Endorecherche patent

Fujisawa claims novel adenosine deaminase inhibitors and their use

Spanish researchers patent an optically active antifungal agent

Antifungal lipopeptides in early development at Fujisawa

Osiris grants mesenchymal stem cell technology rights to JCR

Valera adopted as new name for Hydro Med Sciences

Continuation of phase I VRX-496 trial recommended

Fibromyalgia advisory meeting for Xyrem proof-of-principle trial

Genzyme seeks Japanese approval of Synvisc

Iseganan designated a fast track drug for VAP

Lumiracoxib safe and effective for moderate to severe postsurgical pain

Low incidence of hypoglycemia reported with insulin glargine in diabetics

Pramlintide induces weight loss and slows gastric emptying in insulin-treated diabetics

Metabolic disease treatments to be developed under Amgen/Biovitrum collaboration

Small molecule selectively targeting HER2 selected for development by Pfizer

Dual inhibitors of HER1/HER2 presented at ACS meeting by Bristol-Myers Squibb

SAR leading to potent, selective and orally active JNK inhibitor AS-601245

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...